Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc has demonstrated a robust growth trajectory, with expectations for a sequential EBITDA improvement of $10-15 million in the upcoming quarters, projecting $32.5 million for Q3 and $45 million for Q4. The company's strategic focus on enhancing its legacy Performance Suite MER by 500 basis points to 89% underscores its commitment to operational efficiency and margin enhancement, positioning it favorably for sustained growth. With strong top-line growth exceeding its mid-teens revenue target and significant business advancements in specialty-focused value-based care, Evolent Health is well-positioned for continued outperformance in the healthcare market.

Bears say

Evolent Health is experiencing significant revenue challenges, including an expected loss of approximately $100 million from its legacy Performance Suite, which may contribute to projected revenues of only about $850 million for that segment in 2026. The company's guidance for EBITDA in Q1 is a modest $20 million, with minimal growth anticipated for Q2, reflecting potential stagnation in performance. Furthermore, the reduction in earnings per share estimates for FY2026 and FY2027, coupled with a decreased price target, indicates a deteriorating financial outlook amidst ongoing market rationalization and client exits.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.